Shares of Chimerix Inc. (CMRX) are surging over 35% in pre-market today, after the company announced initiation of a Phase 2/3 study of dociparstat sodium or DSTAT in COVID-19 patients with acute lung injury or ALI.
from RTT - Before the Bell https://ift.tt/2VNxJkh
via IFTTT
No comments:
Post a Comment